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Abstract 
Fosfomycin-tromethamine activity is well established for oral treatment of uncomplicated 
lower urinary tract infections but little is known about its potential efficacy in 
pyelonephritis. Ascending pyelonephritis was induced in mice infected with 6 strains of 
Escherichia coli (fosfomycin MICs: 1 µg/ml to 256 µg/ml). Urine pH was 4.5 before 
infection and 5.5-6.0 during infection. Animals were treated for 24h with fosfomycin (100 
mg/kg subcutaneously every 4 hours) and CFU were enumerated in kidneys 24h after the 
last fosfomycin injection. Peak (20.5 µg/ml at 1h) and trough (3.5 µg/ml at 4h) levels in 
plasma were comparable to those obtained in human after an oral dose of 3 grams. 
Fosfomycin treatment significantly reduced bacterial loads in kidneys (3.65 log10CFU/g 
[min-max=1.83-7.03] and 1.88 log10CFU/g [1.78-5.74] in start-of-treatment control mice 
and treated mice, respectively, P < 10-6). However, this effect was not found to differ 
across the 6 study strains (P = 0.71) and between the 3 susceptible and the 3 resistant 
strains (P=0.09). Three phenomena may contribute to explain this unexpected in vivo 
activity: i) in mice, fosfomycin kidney/plasma concentrations ratio increased from 1 to 7.8 
(95% CI, 5.2; 10.4) within 24 hours; in vitro, when pH decreased to 5: (ii) fosfomycin MICs 
for the 3 resistant strains (64-256 µg/ml) decreased into the susceptible range (16-32 
µg/ml) and: iii) maximal growth rates significantly decreased for all strains and were the 
lowest in urine. These results suggest that local fosfomycin concentrations and 
physiological conditions may favour fosfomycin activity in pyelonephritis, even against 
resistant strains. 
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INTRODUCTION 
Over the last two decades, resistance to β-lactams among Enterobacteriaceae has emerged 
as a major public-health threat. Isolates of Escherichia coli producing extended-spectrum β-
lactamases are currently responsible for a large proportion of urinary tract infections (UTIs), 
in the community as well as in the healthcare setting (1–3). In the current era of increasing 
prevalence of antibiotic resistance, fosfomycin has attracted renewed interest for the 
treatment of infections caused by multidrug-resistant pathogens, and especially UTIs. 
Indeed, it has a broad-spectrum antimicrobial activity and a favorable safety profile (4, 5). 
Fosfomycin-tromethamine, a soluble salt with improved bioavailability over fosfomycin, is 
currently recommended in single-dose as the first-line drug for the treatment of 
uncomplicated lower UTIs in Europe (6) and in the United States (7). However, it is unknown 
whether fosfomycin-tromethamine would be useful for the treatment of pyelonephritis in 
human, raising the questions of kidney diffusion and breakpoints to be used in 
pyelonephritis as compared with cystitis. Indeed, the current susceptibility breakpoint of 
fosfomycin for Enterobacteriaceae is a minimum inhibitory concentration (MIC) of 32 µg/ml 
according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (8). 
We previously demonstrated that fosfomycin resistance in E. coli strains from various 
genetic backgrounds was associated with a decrease of in vitro fitness and in vivo virulence 
in a murine model of pyelonephritis (9). In addition, some mutations conferring fosfomycin 
resistance have been shown to decrease pilus biosynthesis and bacterial adhesion to 
epithelium cells (10, 11). Furthermore, Martin-Gutierrez et al. recently demonstrated that 
anaerobiosis and acidic pH values in urine decreased fosfomycin MICs in strains harboring 
chromosomal resistance mutations (12). Finally, it has been previously shown that high 
concentrations (1000-4000 µg/ml) were achieved in urine after oral administration of 3 g of 
fosfomycin-tromethamine in humans and remained above 100 µg/ml for at least 30-40h 
(13), but data on concentrations in kidneys are scarce. 
However, possible limitations for the use of the oral fosfomycin-tromethamine in 
pyelonephritis may be anticipated, related to potentially low concentrations in kidneys as 
compared to urine, which in turn might be associated with limited bactericidal activity and 
risk of selection of resistant mutants. Indeed, the selection of spontaneous fosfomycin-
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resistant mutants occurs at a very high rate in vitro (between 10-7 to 10-6 cells among Gram-
negatives) (14).  
Therefore, the aim of the present study was to investigate the activity of fosfomycin in a 
murine model of pyelonephritis due to E. coli, using a dosing regimen that reproduced 
plasma concentrations comparable to those obtained in human with the oral formulation of 
fosfomycin-tromethamine. Different strains with increasing levels of MICs were used in 
order to define the in vivo activity of fosfomycin-tromethamine according to strain 
susceptibility in this specific infection. 
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RESULTS   
Bacterial study strains. Characteristics of bacterial strains used in the study are shown in 
Table 1. Three strains were susceptible to fosfomycin and three strains were resistant, 
according to EUCAST breakpoints (32 µg/ml). Mutations in genes known to be involved in 
fosfomycin resistance (uhpB, uhpC, glpT and cyaA) were detected in all strains, including 
those categorized as susceptible (B175 and B56) according to the current EUCAST breakpoint 
(Table 1). All but one strain (E. coli B56, producing an extended spectrum β-lactamase) were 
susceptible to other antibiotic families. 
Fosfomycin concentrations in plasma and kidneys. Fosfomycin concentrations in plasma 
and kidneys after a single injection of 100 mg/kg sc are shown in Table 2. While fosfomycin 
concentrations were comparable in plasma and kidneys 1h following the injection, 
fosfomycin concentrations were higher in kidneys than in plasma over time, with mean 
concentrations at 24h < 1 mg/L in plasma and 6.8 mg/L in kidneys, and a kidney/plasma ratio 
of 7.8 (95% CI, 5.2; 10.4) (Figure 1). After a single injection, area under the concentration-
time curve in kidney (AUC0-24h) was estimated to 166.6 mg.h/L, being two-fold higher than in 
plasma where it reached 85.0 mg.h/L. Fosfomycin AUC0-24h in plasma and kidneys after a 100 
mg/kg injection every 4h for 24h were 357.1 and 614.5 mg.h/L, respectively and AUC in 
plasma to the time a sacrifice (AUC0-44h) was 470.3 mg.h/L.   
Fosfomycin antimicrobial effect in murine pyelonephritis. The bacterial loads in kidneys 
according to fosfomycin treatment and the infective strain are presented in Figure 2 and 
Table 3. Fosfomycin treatment significantly reduced the bacterial loads in kidney (P < 10-6). 
Median (min-max) bacterial loads in kidney were 3.7 log10 CFU/g (1.8-7.0) in start-of-
treatment control mice, and 1.9 log10 CFU/g (1.8-5.7) in fosfomycin-treated mice. However, 
there was no significant difference in kidney bacterial loads according to the infective strain 
(P = 0.71) and between the 3 susceptible and the 3 resistant strains (P = 0.09). The 
interaction between the infective strain and the fosfomycin effect was not significant (P = 
0.53). Similarly, the proportion of sterile kidneys in treated mice did not differ between the 6 
strains (P > 0.8) (Table 3). No fosfomycin-resistant mutant was detected in kidneys at the 
time of sacrifice for any of the 6 strains. 
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Pharmacokinetic/pharmacodynamic (PK/PD) analysis. Fosfomycin AUC0-24/MIC ratios in 
plasma and kidneys according to strains are shown in Table 3. The relationship between the 
bacterial loads in kidneys and the AUC0-24/MIC ratios in plasma or kidney and the AUC0-
44/MIC ratios in plasma were not significant (P=0.45 for both plasma and kidney). 
Effect of pH on fosfomycin activity and bacterial growth rate. In order to explain the 
unexpected activity of fosfomycin against both susceptible and resistant strains, 
investigations were performed to test the influence of acidic pH, as 85% of patients with UTI 
due to E. coli had a urine pH of < 6.5) (12). Indeed, pH in uninfected urine from 5 CBA mice 
before experimental pyelonephritis was 4.5 and ranged from 5.5 to 6.0 in the same mice 
after 48h of experimental pyelonephritis. 
Effect of pH on in vitro fosfomycin activity. Low pH values increased fosfomycin activity 
among fosfomycin-resistant strains (Table 1). Indeed, when pH decreased from 7.2 to 5, 
fosfomycin MICs against the 3 resistant strains decreased from 64-256 µg/ml to 16-32 µg/ml, 
which corresponded to susceptibility according to EUCAST (8).  
Effect of pH and urine on in vitro bacterial growth rate. At pH 7, maximal growth rates 
(MGRs) differed among the 6 studied strains, with median values ranging from 3.29 to 4.20 
h-1 (P < 0.01). For each of the 6 strains, MGR was reduced as the pH was lower (Figure 3). 
This reduction was statistically significant (P < 0.05) between pH 7 and pH 5 for all strains 
except C05. The lowest MGR values were observed in urine with a significant reduction as 
compared with MGR value determined at pH 7 for all strains (P < 0.05). For each of the 6 
strains, time to achieve MGR was prolonged at pH 5 as compared with pH 7 and this 
difference was statistically significant (P < 0.05) for all strains except C05 (Figure 3). 
 
DISCUSSION 
Fosfomycin has been approved for decades as an injectable antibiotic for the treatment of 
systemic infections due to both Gram-positive cocci and Gram-negative bacilli, including 
severe infections (4, 15, 16).  More recently, an oral formulation, fosfomycin-tromethamine, 
has rapidly become the first-line empirical treatment recommended worldwide as a single 
dose for acute uncomplicated lower UTIs (6, 7).  
Here we show that, when given a regimen generating peak and trough levels in plasma in 
the range of those obtained in human after a single dose of the oral formulation of 
fosfomycin-tromethamine (approximatively 20 µg/ml and 5 µg/ml, respectively) (17, 18), 
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fosfomycin produced a significant reduction of bacterial load after 24h of treatment in 
kidneys from mice with pyelonephritis. However, the unexpected result was that fosfomycin 
efficacy was similar whatever the study strains,  susceptible or resistant to fosfomycin, 
according to EUCAST (8). 
Fosfomycin activity observed in infected kidneys may result from the combination of local 
specific physiological conditions in urine and of fosfomycin concentrations in the kidneys. 
Indeed, several authors have already shown that low pH values increased fosfomycin in vitro 
activity (12, 19, 20). In an acidic environment such as urine, fosfomycin is partially 
protonated, being in a more lipophilic state, allowing fosfomycin entry into bacteria, and 
resulting in higher antimicrobial activity (20). Our results support these findings, as low pH 
values were associated with a significant decrease in fosfomycin MIC values for resistant 
strains into the susceptible range (Table 1). Other factors than acidic pH may alter the 
growth of E. coli in urine, such as the lack of essential sources of metabolic elements like 
urea, creatinine, iron, citric acid, D-serine, or ammonia (21). 
In the present study, we also confirmed in vitro that low pH values were associated with a 
decreased in vitro fitness for fosfomycin-susceptible or resistant strains, as previously 
reported (12) and showed that this decrease was maximal in urine for all the tested strains 
(Figure 2). 
Chromosomal mutations conferring fosfomycin resistance have been associated with a high 
biological cost, entailing a reduced fitness (11). This fitness cost is of particular interest in 
uropathogenic E. coli strains because if the biological cost is high, the resistant bacteria will 
not grow at the minimal rate needed to establish infection or to invade the kidney (22, 23). 
We have recently shown in the same model of ascending murine pyelonephritis due to 
uropathogenic E. coli strains belonging to the B2 phylogenetic group that there was a 
significant reduction in kidney infection rates with fosfomycin-resistant isolates as compared 
with susceptible ones (9). This phenomenon may of course have favoured fosfomycin 
antimicrobial activity in mouse pyelonephritis and have contributed to limit the selection of 
fosfomycin-resistant mutants, as observed in the present study in mice with no detection of 
fosfomycin resistance for any strain tested. 
On a pharmacokinetic point of view, fosfomycin concentrations over time were higher in 
kidneys than in plasma. This increase in drug exposure obviously favored fosfomycin activity 
in pyelonephritis. On a PK/PD point of view, recent studies done in mice demonstrated that 
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the PK/PD index that best predicted fosfomycin efficacy in a thigh and in UTI model was 
AUC/MIC ratio (24, 25). More specifically, in the thigh infection model, for E. coli, net stasis 
was observed at a median AUC/MIC ratio value of 19.3 and one-log kill was observed at a 
median AUC/MIC ratio value of 97.5 (24). According to these data, since a similar dosing 
regimen was used in the present study in all mice and generated in plasma the same AUC0-
44h of 470.3 mg.h/L at the time of sacrifice, the target value for net stasis would be achieved 
only for strains with an MIC of 24 µg/ml or lower, and the one-log kill target would be 
achieved only for strains with an MIC of 4 µg/ml or lower. The “higher than expected” 
fosfomycin activity observed in our model (Table 3) is probably the consequence of the 
overall favorable local physiological conditions discussed above, reducing the MIC, fitness 
and virulence of resistant strains and associated with kidney concentrations favouring 
fosfomycin activity in pyelonephritis.  
The lack of correlation we observed between AUC/MIC ratio in plasma and CFUs in kidneys 
was related to the fact that, on one hand, all the mice were treated with the same dosing 
regimen and therefore exposed to the same AUC, and on the other hand, local MICs of 
resistant strains in urine became very similar to those from susceptible strains. Thus, as AUC 
was similar for all strains and MICs in local conditions not as different as in standard 
conditions (Table 1), the AUC/MIC ratio reached a “plateau” that precluded to investigate 
the PKPD relationship and did not allow us to determine an MIC breakpoint.  
Several limitations of our study, due to experimental conditions, should be taken into 
account when extrapolating the data as they could limit the probability for selection of 
fosfomycin-resistant mutants in vivo: i) bacterial loads in kidneys before fosfomycin 
treatment were moderate, and no spontaneous mortality is observed in this model; ii) 
duration of fosfomycin treatment was limited to 24h, a short duration of time to select for 
resistant mutants; however, it must be acknowledge that this is very similar to the situation 
in human after an oral single dose of fosfomycin; iii) the fosfomycin dosing regimen used in 
the present study generated an  AUC0-24h that corresponded approximately to what would 
be obtained in human after two doses of oral fosfomycin-tromethamine (15, 16, 18), as 
repeated oral doses is a dosing regimen that is under investigation for other situations than 
cystitis in women (19); iv) finally, we did not perform a group of end-of-treatment control 
mice which would have help to analyze the relative part of spontaneous bacterial clearance 
from the kidneys and the antibacterial effect of fosfomycin.  
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In conclusion, our results suggest that fosfomycin-tromethamine oral formulation might be 
of interest in human for the treatment of UTI with parenchymal infections, such as 
pyelonephritis, due to favorable local physiological conditions and kidney concentrations. 
Our results suggest that repeated dosing of fosfomycin-tromethamine should be 
investigated for the treatment of uncomplicated pyelonephritis in women.  
 
MATERIALS AND METHODS 
Bacterial strains. 
Six bacterial strains of E. coli were used (Table 1), with MICs of fosfomycin ranging from the 
susceptible to resistant range (1 to 256 µg/ml). The reference wild-type E. coli CFT073 
(O6:K2:H1) strain (25) was previously used to set up a murine model of pyelonephritis by our 
group (26, 27). Other strains were clinical isolates from urinary tract infections (UTIs), except 
E. coli MUT2 that was a fosfomycin-resistant mutant selected in vitro from E. coli CFT073. 
We selected strains belonging to phylogenetic group B2 since such strains are most 
frequently responsible for UTIs in humans and carry the most important virulence factors 
(28, 29). 
In vitro fosfomycin activity. MICs of fosfomycin (Sanofi-Aventis, Paris, France) were 
determined by the dilution method in Mueller-Hinton agar (pH 7.2) in accordance with 
EUCAST guidelines (9), with 25 µg/ml glucose-6-phosphate (G6P) (Sigma–Aldrich, Saint-
Quentin Fallavier, France) added in the medium. MICs of fosfomycin were also determined 
at pH 5 and 6. Each in vitro experiment was replicated at least in three independent 
experiments and the median values were reported for each strain.   
Mechanisms of fosfomycin resistance. Known mechanisms of fosfomycin resistance were 
determined for each strain exhibiting an MIC of fosfomycin ≥8 µg/ml as several of them have 
been found in strains with MICs from the susceptible range (9). Mutations in the genes 
involved in fosfomycin chromosomal resistance (i.e., murA, glpT, uhpT, cyaA, ptsI, uhpA, 
uhpB, uhpC) were determined by nucleotide sequencing after amplification by PCR, as 
previously described (9). The amino acid sequences were compared with those of E. coli 
CFT073 and K-12.  
In vitro bacterial growth rate. Growth rates at 37°C were measured in Luria-Bertani (LB) 
broth with various pH (5, 6, and 7) and in sterile-filtered pooled human male urine (pH=6), as 
previously described (9). For each strain and condition, maximal growth rate (MGR) and time 
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to achieve MGR (Tmax) were measured in three independent experiments and the median 
values were reported for each strain. 
Murine pyelonephritis model. We used the ascending, unobstructed UTI mouse model 
previously developed by our group (26, 27). Eight-week-old immunocompetent CBA female 
mice (weight 20–23 g) were used. Bacterial inocula were obtained by overnight incubation in 
LB broth followed by centrifugation at 8000 × g for 15 min. Pellets were suspended in 1 mL 
of sterile saline solution to a final inoculum of 109 CFU/ml. Pyelonephritis was induced after 
general anesthesia (with an intraperitoneal administration of 150 mg/kg of body weight of 
ketamine and 0.5 mg/kg xylazine) by injecting 50 μL (107 CFU of E. coli) into the bladder 
through a urethral catheter. Urine was sampled for pH was determination in 5 mice just 
before bacterial inoculation and 48h after infection. For each strain, 18-24 mice were 
infected. Two days after inoculation, 8 to 14 mice were sacrificed before treatment (start-of-
treatment controls), and 9-10 were treated over 24h by subcutaneous injections (fosfomycin 
100 mg/kg q4h for 24h). In order to avoid unnecessary mice killing, we did not constitute a 
group of untreated mice (end-of-treatment controls) because previous study setting up the 
model showed that bacterial counts in kidney were stable for at least 5 to 10 days (26). 
Treated mice were sacrificed 24h after the last antibiotic injection to avoid the carry-over 
effect. Kidneys were aseptically removed and were homogenized in 1 mL of saline solution. 
Then, 100 μL of the solution or its dilution were spread onto MH agar plates and incubated 
at 37°C for 24 h. Selection of resistant mutants after in vivo exposure was sought by plating 
100 µL of kidney homogenates onto MH agar containing fosfomycin at a concentration of 4 
times the MIC for fosfomycin-susceptible strains and 2 times the MIC for fosfomycin-
resistant strains. Kidneys were considered sterile if no colony grew on agar plate. In the 
absence of bacterial growth, the log10 CFU/g of kidney was calculated considering the 
growth of one colony and the weight of the kidney, as the method detection limit. This 
corresponded approximately to 1.8 log10 CFU/g of kidney. Assessment criteria for each strain 
were: i) bacterial load in kidneys expressed as log10 CFU/g; ii) the percentage of sterile 
kidneys. 
Fosfomycin dosing regimen. Single-dose plasma pharmacokinetic studies were performed 
on eight-week-old CBA female mice (weight 20–23 g) in order to determine the therapeutic 
regimen that best reproduced peak and trough plasma levels obtained in humans with a 
daily oral-dose of 3 grams of fosfomycin-tromethamine (20 and 5 µg/ml, respectively) (15, 
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18, 19). Dosing interval was chosen accordingly to reproduce area under the concentration-
time curve (AUC) in the range of that obtained in humans with a single oral-dose of 3 grams 
of fosfomycin-tromethamine (ie up to 228 mg.h/liter, as compared with a range of 1400 to 
1800 mg.h/L in human with the iv route) (13, 15, 18) since fosfomycin AUC/MIC ratio is the 
PK/PD index most closely linked to in vivo efficacy (24). This regimen was determined as 100 
mg/kg every 4 h (15, 18, 19). Total drug concentrations were utilized in PK/PD analyses, as 
fosfomycin is not bound to plasma protein (15, 18).  
Fosfomycin sampling in plasma and kidney. Blood samples of at least 500 µL were obtained 
by intracardiac puncture from 4 anesthetized mice at 5 different intervals after a single 
subcutaneous injection of fosfomycin (100 mg/kg): 1h, 2h, 4h, 6h and 24h. After blood 
collection, plasma was separated by centrifugation. Kidneys were also removed at the same 
sampling times. 
Fosfomycin assays in plasma and kidneys. Concentrations of fosfomycin were determined 
using a triple quadrupole mass spectrometer, AquityÒ TQD (Waters, St Quentin en Yvelines), 
operated with negative electrospray ionization. Instrument parameters were optimized for 
fosfomycin (137 -> 79 m/z) and propylphosphonic acid (internal standard) (123 -> 79 m/z) 
transitions. Fosfomycin was extracted from samples (plasma and kidneys) via protein 
precipitation with acetonitrile. The chromatographic separation took place on an AcquityÒ 
UPLC BEH HILIC column with the dimensions 100 mm x 2.1 mm and 1.7 µm particle size 
(Waters, St Quentin en Yvelines). The lower limit of quantitation was 1 mg/L. Intraday and 
inter-day coefficients of variation in plasma were 8.5 and 11.1%, respectively, at 
concentrations ranging from 5 to 250 µg/ml. The possible influence of co-extracted matrix 
compound on detectability of target analyses was checked.  
Fosfomycin PK/PD analysis. For the PK analysis, concentration data of fosfomycin in plasma 
and kidney were separately fitted to 2-compartments models with extravascular 
administration (30), pooling data of all mice and using the ‘optim’ package of R statistical 
software (v3.4.0). For each fit, the pharmacokinetic model could thus be written as: 
. Parameters to be estimated were A and B, first and 
second macro-constants; α and β, first and second-rate constants, and ka, absorption rate 
constant. Data below the LLOQ were imputed to the LLOQ. We derived the AUC0-24h in 
plasma (AUC0-24h,plasma) and kidney (AUC0-24h,kidney) and in in plasma to the time of sacrifice 
(AUC0-44h) from the model with a 100mg/kg administration of fosfomycin every 4 hours. 
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Finally, AUC0-24h/MIC ratios were determined in plasma and kidneys for each strain used in 
the murine pyelonephritis model. We studied the relationship between the bacterial load in 
kidney and AUC0-24h/MIC ratios in plasma or kidney using linear regressions. 
Statistical analysis. MGRs of bacterial strains at pH 7, and studied the effect of pH on MGRs 
and time to achieve MGR using a Kruskall-Wallis non parametric test.  
A 2-way analysis of variance was performed to study the effect of the infective strains and 
fosfomycin treatment on the bacterial loads in kidneys, and tested the interaction between 
the infective strain susceptibility and the treatment effect. We also compared the proportion 
of sterile kidney in fosfomycin-treated mice according to the infective strain using a Fisher 
exact test. Bacterial loads in kidneys from treated mice were compared between the 3 
susceptible and the 3 resistant strains by the Mann and Whitney non parametric test. The 
relationship between the bacterial load in kidney and the AUC0-24h/MIC and AUC0-44h/MIC 
ratios in plasma and the AUC0-24h/MIC ratio in kidneys was studied using linear regression. 
Type-I error was set at 0.05, and two-tailed tests were used. All analyses were performed 
using R statistical software. 
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Figure 1. Ratio of the kidney/plasma fosfomycin concentrations in CBA mice after a single 
injection of 100 mg/kg sc.   
Curve represents the mean ratio predicted by the model.  Dark area represents the 95% 
confidence interval of the prediction. Each point represents the observed ratio for each 
sample. 
Figure 2. Bacterial counts (log10 CFU per gram of kidney) of E. coli in mice with pyelonephritis treated or not for 24h with fosfomycin 100 mg/kg 
sc every 4 hours, according to study strains. 
“No fosfomycin treatment” groups corresponded to start-of-treatment control mice.  Each circle represents a mouse; horizontal bars represent 
median values. Fosfomycin treatment significantly reduced the bacterial loads in kidney (P<10-6).  The effect of the infective strain on the 
bacterial load in kidney was not significant (P = 0.53), as was the interaction between the type of strain and the fosfomycin effect (P = 0.71). 
Figure 3. In vitro maximal growth rates (upper panel) and time to achieve maximal growth 
rate (lower panel) for each study strain according to pH in Luciani-Bertani or in urine. Each 
value is the median of three independent experiments. Brackets represent standard 
deviations. 
MGR was significantly reduced (P < 0.05) in urine as compared with pH7 for all strains and at 
pH5 for all strains except C05. 
Time to achieve MGR (Tmax) was significantly prolonged (P < 0.05) at pH 5 as compared with 
pH 7 for all strains except CO5. 
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Table 1. Susceptibility to fosfomycin of E. coli strains used in this study, according to pH and media. 
Strains CFT073 B56 B175 MUT2 C05 C114 
Origin Urine clinical 
isolate 
Urine clinical 
isolate 
Urine clinical 
isolate 
Mutant from 
CFT073 
Urine clinical 
isolate 
Urine clinical 
isolate 
Phylogenetic group B2 B2 B2 B2 B2 B2 
Fosfomycin MIC* according to pH: 
pH 7.2 1 8 32 64 128 256 
pH 6 1 8 32 16 64 32 
pH 5 1 16 32 16 32 32 
Susceptibility categorization 
according to pH 7.2/pH 5* * 
S / S S / S S / S R / S R / S R / S 
Detected mutation(s) of 
fosfomycin resistance 
None UhpB (P169S) CyaA (L125F), 
UhpC (T72I) 
UhpB 
(G469R) 
UhpC (Q210X) UhpC (Q132X), 
GlpT (G144D) 
*: MICs are in µg/ml 
**: S denotes susceptible and R resistant, according to EUCAST breakpoints 7 
Table 2. Fosfomycin concentrations in plasma and kidneys from CBA female mice after a 
single injection of 100 mg/kg given subcutaneously. Each set of values for a given sample 
time corresponds to the mean of 4 mice (min-max).  
Fosfomycin concentrations (µg/ml) in: 
Time Plasma Kidneys 
1h 20.5 (9.0 – 33.5) 20.8 (11.4 – 27. 5) 
4h 3.5 (2.8 – 4.8) 8.4 (6.7 – 11.4) 
24h < 1 (<1 - < 1) 6.8 (4.0 – 10.1) 
Table 3. Pharmacokinetics/pharmacodynamics of fosfomycin (FOS) in murine pyelonephritis due to E. coli after a 24h treatment. 
Strains FOS MIC 
(µg/ml) 
FOS AUC0-24 
plasma/MIC 
FOS AUC0-24 
kidney/MIC 
Median log10 CFU counts/g of kidneys 
 [range min-max] 
Start-of-treatment control mice 
(sterile/ total) 
FOS treated mice 
(sterile/ total) 
CFT073 1 357.1 614.5 3.9 [1.9-5.3] (0/11) 2.0 [1.8-5.1] (4/9) 
B56 8 44.6 76.8 3.0 [2.5-6.5] (0/11) 1.8 [1.8-2.8] (4/10) 
B175 32 11.2 19.2 3.4 [2.1-7.0] (0/11) 1.9 [1.8-4.9] (4/10) 
MUT2 64 5.6 9.6 3.7 [2.2-6.8] (0/12) 1.9 [1.8-5.5] (5/10) 
C05 128 2.8 4.8 3.7 [2.3-4.9] (0/8) 2.7 [1.9-4.1] (3/10) 
C114 256 1.4 2.4 3.7 [1.8-5.8] (0/14) 1.9 [1.8-5.7] (6/10) 
CFU: colony-forming units, FOS: fosfomycin, MIC: minimum inhibitory concentration. Median (min-max) bacterial loads in kidney were 3.7 
log10 CFU/g (1.8; 7.0) in start-of-treatment control mice, and 1.9 log10 CFU/g (1.8; 5.7) in fosfomycin-treated mice (P<10-6). Lower limit of 
detection was 1.8 log10 CFU/g of kidney.  
